10-Q: Kiromic Biopharma Reports Second Quarter 2024 Results Amidst Going Concern Uncertainty

Kiromic Biopharma's Q2 2024 results reveal ongoing losses and a precarious financial position, raising substantial doubt about the company's ability to continue as a going concern.

Summary

• Kiromic Biopharma reported a net loss of $6.825 million for the three months ended June 30, 2024, and a net loss of $12.973 million for the six months ended June 30, 2024.
• The company's research and development expenses increased significantly, reaching $4.135 million for the three months and $7.157 million for the six months ended June 30, 2024.
• General and administrative expenses were $2.218 million for the three months and $4.309 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents were $4.048 million as of June 30, 2024, with a total of $4.179 million including restricted cash.
• Kiromic has relied on equity and debt financing to fund operations and has an accumulated deficit of $135.9 million as of June 30, 2024.
• The company has issued twenty senior secured convertible promissory notes totaling $41.2 million through June 30, 2024.
• The company is currently in discussions with financing sources to secure short-term funding, but existing cash resources may not be sufficient beyond November 2024.

Sentiment

Score: 2

Explanation: The document indicates a very negative sentiment due to the company's significant losses, negative cash flow, going concern warning, and reliance on debt financing. The company's future is highly uncertain without securing additional funding.

Positives

• The company has enrolled six patients in the Deltacel-01 clinical trial, with five entering the long-term follow-up phase.
• The average Progression-Free Survival (PFS) for the five patients evaluated in the Deltacel-01 trial is 4.8 months, with one patient achieving 8 months.
• Kiromic has activated four clinical trial sites for the Deltacel-01 study and expects to add another by the end of August 2024.
• The company submitted a Fast-Track Designation (FTD) Application to the FDA for its Deltacel product.

Negatives

• The company has incurred significant losses and negative cash flows from operations since inception.
• Kiromic does not have sufficient cash on hand to meet its obligations through the next twelve months.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may need to file for bankruptcy if it cannot secure additional financing.
• The company has not generated any revenue from product sales to date.
• The company's accumulated deficit is $135.9 million as of June 30, 2024.

Risks

• The company's ability to obtain regulatory approval and market acceptance of its product candidates is uncertain.
• The company is dependent on third-party clinical research organizations and manufacturers.
• The company faces risks related to intellectual property protection and potential litigation.
• The company's ability to attract and retain employees is critical to its success.
• The company is subject to fluctuations in general economic and business conditions.
• The company's principal stockholder has significant influence over the company's direction.
• The company is subject to a potential governmental investigation.

Future Outlook

The company plans to continue the development of Isocel and Procel once sufficient financial support is secured, with IND submissions expected in the second half of 2025 and the second quarter of 2026, respectively. The company is also seeking short-term financing to continue operations and fund liquidity needs through the end of the year.

Management Comments

• Management is evaluating different strategies to obtain the required funding for future operations.
• Management anticipates that existing cash resources will not be sufficient to meet operating and liquidity needs beyond November 2024.
• Management may further evaluate additional cost reduction actions, including additional reductions in the company's workforce and delay of research and development expenditures.

Industry Context

The company is operating in the competitive biopharmaceutical industry, specifically in the development of cell therapies for solid tumors. The company's focus on allogeneic Gamma Delta T-cell therapies and proprietary technologies positions it within a growing area of research, but it faces challenges in securing funding and navigating regulatory hurdles.

Comparison to Industry Standards

• Kiromic's financial results are concerning when compared to industry standards for biotech companies at a similar stage of development.
• Many biotech companies at this stage are able to secure significant funding through venture capital or strategic partnerships, which Kiromic has struggled to do.
• The company's high operating losses and negative cash flow are not uncommon for early-stage biotech companies, but the lack of a clear path to profitability and the going concern warning are significant red flags.
• Compared to companies like Allogene Therapeutics or Fate Therapeutics, which are also developing allogeneic cell therapies, Kiromic's financial position appears weaker, and its clinical progress is slower.
• The company's reliance on convertible promissory notes for financing is a high-risk strategy, as it can lead to significant dilution and financial instability.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation related to the Jason Terrel claim.
• The company has settled in principle the Karp and Podmore class action lawsuits.

Stakeholder Impact

• Shareholders face significant risk due to the company's precarious financial position and potential for bankruptcy.
• Employees may be impacted by potential workforce reductions and delays in research and development programs.
• Customers and suppliers may be affected by the company's financial instability and potential for disruption.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company plans to continue the development of Isocel and Procel once sufficient financial support is secured.
• The company expects to begin enrolling patients in the Expansion Phase of the Deltacel-01 trial in September.
• The company expects to receive a response from the FDA regarding its Fast-Track Designation (FTD) Application within two months of the submission.
• The company may consider petitioning for early termination of the Deltacel-01 Phase 1 study in the first half of 2025, contingent upon demonstrated clinical benefits and the absence of toxicities.

Key Dates

Keywords

Biopharma, Gamma Delta T-cell therapy, Deltacel, Isocel, Procel, Clinical Trials, Going Concern, Promissory Notes, FDA, Oncology